Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. STAA
stocks logo

STAA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
76.92M
+57.14%
0.140
-127.26%
71.59M
+68.09%
0.016
-101.59%
84.88M
+91.51%
0.138
-208.07%
Estimates Revision
The market is revising Downward the revenue expectations for STAAR Surgical Company (STAA) for FY2025, with the revenue forecasts being adjusted by -1.03% over the past three months. During the same period, the stock price has changed by -4.80%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-83.91%
In Past 3 Month
Stock Price
Go Down
down Image
-4.80%
In Past 3 Month
Wall Street analysts forecast STAA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STAA is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast STAA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STAA is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
Current: 26.600
sliders
Low
28.00
Averages
28.00
High
28.00
Current: 26.600
sliders
Low
28.00
Averages
28.00
High
28.00
Stifel
Buy
to
Hold
downgrade
$20 -> $28
2025-08-07
Reason
Stifel
Price Target
$20 -> $28
2025-08-07
downgrade
Buy
to
Hold
Reason
Stifel downgraded Staar Surgical (STAA) to Hold from Buy with a price target of $28, up from $20, following the proposed acquisition by Alcon (ALC). The acquisition makes sense strategically and the valuation paid appears attractive for Alcon, the analyst tells investors in a research note.
Stifel
Thomas Stephan
Buy
to
Hold
downgrade
$20 -> $28
2025-08-06
Reason
Stifel
Thomas Stephan
Price Target
$20 -> $28
2025-08-06
downgrade
Buy
to
Hold
Reason
Stifel analyst Thomas Stephan downgraded Staar Surgical to Hold from Buy with a price target of $28, up from $20.
Sidoti
James Sidoti
Buy -> Neutral
downgrade
$28
2025-08-05
Reason
Sidoti
James Sidoti
Price Target
$28
2025-08-05
downgrade
Buy -> Neutral
Reason
Sidoti analyst James Sidoti downgraded Staar Surgical (STAA) to Neutral from Buy with a $28 price target after Alcon (ALC) announced a definitive agreement to acquire Staar for $28 per share in cash.
Mizuho
Neutral
maintain
$17 -> $18
2025-07-16
Reason
Mizuho
Price Target
$17 -> $18
2025-07-16
maintain
Neutral
Reason
Mizuho raised the firm's price target on Staar Surgical to $18 from $17 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Canaccord
Hold
maintain
$17 -> $20
2025-05-08
Reason
Canaccord
Price Target
$17 -> $20
2025-05-08
maintain
Hold
Reason
Canaccord raised the firm's price target on Staar Surgical to $20 from $17 and keeps a Hold rating on the shares. The firm said they delivered an expectedly tough Q1 in terms of its results, but the tone of the earnings call was more upbeat than expected especially given that guidance was withdrawn, and as a result, the firm is taking its estimates up.
Stephens & Co.
Mason Carrico
Hold
Reiterates
$17
2025-03-18
Reason
Stephens & Co.
Mason Carrico
Price Target
$17
2025-03-18
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for STAAR Surgical Co (STAA.O) is 52.78, compared to its 5-year average forward P/E of 72.28. For a more detailed relative valuation and DCF analysis to assess STAAR Surgical Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
72.28
Current PE
52.78
Overvalued PE
132.21
Undervalued PE
12.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
49.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
104.95
Undervalued EV/EBITDA
-6.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.21
Current PS
0.00
Overvalued PS
17.59
Undervalued PS
2.82
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 140.85% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 140.85% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

STAA News & Events

Events Timeline

(ET)
2025-11-10
08:47:47
Staar Surgical Investor Discusses Changes to Sale Agreement with Alcon
select
2025-11-07 (ET)
2025-11-07
10:11:40
Staar Surgical Reveals Changes to Alcon Merger Deal
select
2025-11-05 (ET)
2025-11-05
16:15:56
Staar Surgical announces Q3 earnings per share of 18 cents, below consensus estimate of 25 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-27Barron's
Staar Surgical and Gold Royalty Experience Activist Involvement

  • Filing Overview: The disclosures are based on 13D filings with the SEC, which are required when an entity acquires more than 5% of a company's securities.

  • Reporting Requirements: Any subsequent changes in holdings or intentions must be reported through amended filings within a specified timeframe.

  • Timeframe of Disclosures: The material discussed pertains to filings made between November 20 and November 26, 2025.

  • Source of Information: The information is sourced from VerityData.

[object Object]
Preview
8.0
11-12NASDAQ.COM
Significant Options Activity on Tuesday: SITE, FIVE, STAA

  • Five Below Inc Options Trading: Five Below Inc (FIVE) experienced a significant options trading volume of 7,345 contracts, equating to about 734,500 underlying shares, with notable activity in the $155 strike call option expiring on November 21, 2025.

  • Staar Surgical Co Options Trading: Staar Surgical Co (STAA) recorded an options trading volume of 8,003 contracts, representing approximately 800,300 underlying shares, highlighted by high activity in the $25 strike put option expiring on March 20, 2026.

  • Comparison of Trading Volumes: The trading volumes for both companies reflect a substantial percentage of their average daily trading volumes over the past month, with FIVE at 71.9% and STAA at 64.9%.

  • Further Information: For additional details on available expirations for options related to SITE, FIVE, or STAA, StockOptionsChannel.com can be visited.

[object Object]
Preview
8.5
11-07Newsfilter
STAAR Surgical Reveals Changes to Alcon Merger Deal

  • Go-Shop Period: STAAR Surgical has initiated a 30-day go-shop period allowing it to actively solicit third-party proposals until December 6, 2025, while still protecting Alcon's merger offer.

  • No Termination Fee: STAAR will not incur a termination fee if it decides to accept a superior proposal from another bidder during the go-shop period, incentivizing other parties to submit offers.

  • Alcon's Waivers: Alcon has waived its matching rights and information rights during the go-shop period, facilitating a more open solicitation process for STAAR.

  • Postponed Stockholder Meeting: The Special Meeting of STAAR stockholders to vote on the Alcon merger has been postponed to December 19, 2025, to allow time for potential third-party proposals.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is STAAR Surgical Co (STAA) stock price today?

The current price of STAA is 26.6 USD — it has increased 0.87 % in the last trading day.

arrow icon

What is STAAR Surgical Co (STAA)'s business?

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

arrow icon

What is the price predicton of STAA Stock?

Wall Street analysts forecast STAA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STAA is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is STAAR Surgical Co (STAA)'s revenue for the last quarter?

STAAR Surgical Co revenue for the last quarter amounts to 94.73M USD, increased 6.93 % YoY.

arrow icon

What is STAAR Surgical Co (STAA)'s earnings per share (EPS) for the last quarter?

STAAR Surgical Co. EPS for the last quarter amounts to 0.18 USD, decreased -10.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for STAAR Surgical Co (STAA)'s fundamentals?

The market is revising Downward the revenue expectations for STAAR Surgical Company (STAA) for FY2025, with the revenue forecasts being adjusted by -1.03% over the past three months. During the same period, the stock price has changed by -4.80%.
arrow icon

How many employees does STAAR Surgical Co (STAA). have?

STAAR Surgical Co (STAA) has 1157 emplpoyees as of December 05 2025.

arrow icon

What is STAAR Surgical Co (STAA) market cap?

Today STAA has the market capitalization of 1.32B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free